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CLINICAL CARE AND TECHNOLOGY

Timing of CGM initiation in pediatric diabetes: The CGM TIME
Trial
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Abstract
Objective: To determine whether timing of CGM initiation offering low glucose sus-
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pend (LGS) affects CGM adherence in children and youth starting insulin pump
therapy.
Methods: A 5-site RCT of pump-naïve subjects (aged 5-18 years) with type 1 diabetes
(T1D) for at least 1 year compared simultaneous pump and CGM initiation offering
LGS vs standard pump therapy with CGM initiation delayed for 6 months. Primary
outcome was CGM adherence (hours per 28 days) (MiniMed™ Paradigm™ Veo™
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system; CareLink Pro™ software) over 6 months after CGM initiation. Secondary
outcome HbA1c was measured centrally. Linear mixed-models and ordinary least
squares models were fitted to estimate effect of intervention, and covariates baseline
age, T1D duration, HbA1c, gender, ethnicity, hypoglycemia history, clinical site, and
association between CGM adherence and HbA1c.
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Results: The trial randomized 144/152 (95%) eligible subjects. Baseline mean age
was 11.5 ± 3.3(SD) years, T1D duration 3.4 ± 3.1 years, and HbA1c 7.9 ± 0.9%. Six
months after CGM initiation, adjusted mean difference in CGM adherence was
62.4 hours per 28 days greater in the Simultaneous Group compared to Delayed
Group (P = .007). There was no difference in mean HbA1c at 6 months. However, for
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each 100 hours of CGM use per 28-day period, HbA1c was 0.39% (95% CI 0.10%0.69%) lower. Higher CGM adherence was associated with reduced time with glucose >10 mmol/L (P < .001).
Conclusion: CGM adherence was higher after 6 months when initiated at same time
as pump therapy compared to starting CGM 6 months after pump therapy. Greater
CGM adherence was associated with improved HbA1c.
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Continuous glucose monitoring (CGM) may improve glycemic control

1.1

|

Study intervention

and quality of life in individuals with type 1 diabetes. Uptake of and
adherence to CGM has been studied in adults, children, and youth

Participants received the Medtronic Veo™ pump, Contour® Link BG

with type 1 diabetes with significant differences between these

meter, Medtronic Enlite™ sensors (under a Health Canada Investiga-

1-8

populations.

The studies are not directly comparable due to meth-

tional Testing Authorization until fully approved by Health Canada in

odological differences. A common finding in all age groups was the

April 2013), Minilink™ REAL-Time transmitter, and CareLink™ Per-

positive correlation between proportion of time spent using CGM and

sonal software. All participants received standard diabetes care for

improvements in glycemic control1-8; CGM adherence was signifi-

children and youth at their site including the same insulin formula-

1,3,4,7

Low glucose sus-

tions, multidisciplinary diabetes care and education; multiple daily

pend (LGS) feature of CGM has been demonstrated to reduce

injections were rarely used. Diabetes nurse educators were trained to

frequency of hypoglycemia without compromising safety or glycemic

provide identical pump and CGM teaching to participants in the two

control.9,10 However, the effect of timing of CGM initiation with

randomization groups.12 Pump training included two pump training

option of LGS on glycemic control has not been explored in pediatrics.

sessions, CareLink™ training, daily telephone calls for the first 10 days

We hypothesized that simultaneous initiation of CGM offering LGS

after pump initiation, and a telephone education session 1 month

and insulin pump therapy in children and youth will be associated with

after pump start. CGM support was provided by four phone calls in

greater CGM adherence than their later initiation. Our study's objec-

the first 10 days after CGM initiation, and telephone education

tive was to determine whether timing of CGM initiation offering LGS,

1 month later. Training and programming of pump and CGM settings

simultaneously with pump initiation or 6 months later, affects CGM

were standardized for all subjects, including use of saline via the pump

adherence and/or HbA1c over the subsequent 6 months in children

and insulin via injections during the first week.11,12 The only differ-

and youth with type 1 diabetes. The trial was performed in 2011 to

ence between randomization groups was the timing of the CGM edu-

2014, when currently used sensors were not available, CGM was not

cation sessions relative to the pump education sessions.

cantly lower in children and youth than adults.

commonly used before pump therapy, and time-in-range was not the

LGS feature was activated in second week of CGM use, and other

standard for reporting glycemic control. We feel that our findings are

CGM settings were initiated in standardized and individualized step-

still relevant and that the main results are generalizable as CGM

wise fashion developed by the Study Group.13 Participants were

becomes more user-friendly each year.

instructed to upload pump and CGM data every week to CareLink™
on home computers.

1

|

RESEARCH DESIGN AND METHODS
1.2

|

Study outcomes

The CGM TIME Trial was a 12-month multicenter randomized controlled trial. Children and youth with type 1 diabetes for at least 1 year

The primary study outcome was CGM adherence expressed as mean

who were initiating insulin pump therapy were randomly assigned to

hours per 28 days for each of the six 28-day periods following initia-

start CGM offering LGS with their pump start (Simultaneous Group)

tion of CGM. CGM initiation occurred at the first study visit for the

or 6 months later (Delayed Group). Randomization was performed

Simultaneous Group, and at the 6-month visit for the Delayed Group.

centrally, stratified by study center and by age (5-12 years vs

When at least 21 days of complete data were available within a given

13-18 years), using a computer-generated randomization schedule

28-day block, a projected 28 day time period was calculated: (Total

with variable block size. Full details of the protocol have been publi-

number of CGM hours in a 28-day period/Days of CGM usage in a

shed.11 There were no upper or lower limits for baseline HbA1c. Par-

28-day period) × 28 days.

ticipants were required to meet provincial criteria for starting insulin

The main secondary outcome was HbA1c, analyzed centrally at

pump therapy which include duration of diabetes (≥1 year), glycemic

baseline, 6 and 12 months (Roche Diagnostics Turbidimetric Inhibition

control (HbA1c <10%), and regular blood glucose monitoring and

Immunoassay, utilizing the DCCT/NGSP formula, Dynacare Laborato-

clinic visits. There was no run-in period to establish participants'

ries, Toronto, Canada). Validated questionnaires evaluating readiness

acceptance and willingness to wear CGM. Informed consent, plus

for making behavior change14 and fear of hypoglycemia15 were col-

assent where indicated, was required. The trial was approved by the

lected for participants and their parents. A brief de novo questionnaire

Institutional Ethics Boards of each participating site. CONSORT Stan-

at the 12 month visit assessed participants' and parents' likelihood of

dards for design and reporting of clinical trials were followed.

continuing to use CGM.
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Adverse events were collected on severe hypoglycemia and

sample size was largest. A time2 term was included to allow for non-

severe hyperglycemia. Severe hypoglycemia was defined as an event

linearity. The estimates from the models were reported along with stan-

requiring assistance from another individual to administer carbohy-

dard errors and 95% confidence interval.

drate, glucagon or other resuscitative efforts due to altered conscious-

HbA1cs within each randomization group were summarized with

ness, seizure or coma. Severe hyperglycemia was defined as a

mean and SD at study entry, 6 months, and 12 months. Student's t test

hyperglycemic event involving all of the following: serum ketones or

was used to compare the mean HbA1cs of the randomization groups

large/moderate urine ketones, arterial blood pH < 7.30 or venous

6 months after CGM initiation, as well as change in HbA1c between

pH < 7.24, serum bicarbonate <14, and treatment in hospital.

study entry and 6 months after CGM initiation. Ordinary least squares
regression was used to determine the effect of various parameters on
HbA1c 6 months after CGM initiation; covariates included baseline

1.3

|

Sample size and statistical analyses

HbA1c, gender, age group, randomization group, ethnicity (Caucasian
vs non-Caucasian), history of severe hypoglycemia in the 12 months

Sample size was based on the primary outcome measure CGM use in

before study entry, and site.

hours per 28 days (ie, 6 time periods before the 6 month visit for the

Average CGM adherence over the six time periods was used to

Simultaneous Group and before the 12 month visit for the Delayed

analyze association between CGM adherence and HbA1c 6 months

Group). Assuming a SD of 56.4 hours (weighted average of SDs in the

after CGM initiation and area under the curve for projected time

15-24 and 8-14 year age groups in two pediatric studies1,2 and all-

spent in hypoglycemia <3.9 mmol/L (70 mg/dL) and hyperglycemia

owing for a 10% dropout rate, 64 participants per group provided

>10 mmol/L (180 mg/dL). Ordinary least squares regression was used

80% power with a type 1 error rate at .05 to detect a difference in

for both sets of analyses, with a restricted cubic spline technique

CGM adherence of 403.2 hours per 28 days which equates to 60%

applied to allow for non-linear effect of CGM hours. HbA1c analysis

adherence which was demonstrated to be a clinically important

was adjusted for baseline HbA1c, age group, gender, site, ethnicity,

threshold for CGM adherence in children in the landmark CGM

and history of severe hypoglycemia. The hypoglycemia and hypergly-

1

study. This sample size could also detect a difference in HbA1c of

cemia analyses included cluster adjustment and adjustment for age

0.5% at 6 or 12 months with a SD of 0.93 (weighted average of SDs

group, gender, and site.

at 6 months from two pediatric CGM studies1,2). To increase power

A P-value of less than .05 was deemed statistically significant.

for secondary outcomes of readiness for change and fear of hypogly-

Statistical analysis was performed by the CHEO Research Institute

cemia, sample size was set at maximum of 150.

using R version 3.4.2.16

Demographic characteristics were described by randomization
group. Categorical variables were summarized in proportions, and
continuous variables with normal distributions with mean and SD.

2

RE SU LT S

|

Comparisons between randomization groups were tested for statistical significance using Student's t test for age, duration of diabetes,

2.1

|

Study population

and HbA1c. Chi square or Fisher's exact test were used as appropriate
for the categorical variables of age group, gender, ethnicity, and his-

Three hundred and fifty-three children and youth with type 1 diabetes

tory of severe hypoglycemia in the 12 months prior to study entry.

were assessed for eligibility (CONSORT Flow Diagram, Supporting

The Student's t test was used to examine the univariate association

Information Figure 1), which required all participants to be naïve to

between mean CGM hours and randomization groups in each of the

pump and CGM. One hundred and fifty-two met the inclusion criteria

six 28-day time periods after CGM initiation. Fisher's exact test was

and 94.7% consented to participation. One hundred and forty-four

used to compare percentages of participants not using CGM and

participants were randomized, with 73 allocated to Simultaneous

those using CGM >60% of the time for each randomization group in

Group and 71 to Delayed Group. Following randomization, 139 partici-

each 28-day block after CGM initiation. Chi square test was used to

pants started pump therapy. There were no significant differences

compare CGM satisfaction scores between randomization groups.

between groups in mean age, age category, diabetes duration, ethnic-

Generalized linear mixed modeling examined association between

ity, or history of severe hypoglycemia in the 12 months before study

randomization group and CGM adherence over time. Covariates

entry (Table 1). The Simultaneous Group had higher HbA1c at study

included age group, gender, ethnicity (Caucasian vs non-Caucasian), his-

entry (8.05% +/− 1.01% vs 7.72% +/− 0.88%, P = .024) (Table 1).

tory of severe hypoglycemia in the 12 months before study entry, site,
time, time2, and an interaction factor between time and randomization
group. The intercept and time (the six 28-day periods) were specified as
random effects while randomization group and its interaction with time

2.2 | Association between timing of CGM initiation
and subsequent CGM adherence

were specified as fixed effects. These within-participant random effects
allowed for better understanding of the variability in CGM adherence

Complete information on CGM adherence in the first 6 months of

and the correlation of CGM adherence between baseline and subse-

CGM was available for 124 participants. CareLink™ collected incom-

quent time points. Site 1 was chosen as the reference group, as its

plete CGM adherence information from 15 separate participants in

282

LAWSON ET AL.

Site 1

Site 2

Site 3

Site 4

Site 5

750

700

Simultaneous (95%CI)

650

Delayed (95%CI)

600

550

CGM hours

500

450

400

350

300

250

200

150

100

50

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

Period (28−day cycles)
F I G U R E 1 Comparison of mean CGM adherence in the Simultaneous and Delayed Groups in the six 28 day periods after the introduction of
CGM, separated by (A) study site and (B) the child’s gender

37 time periods. Five patient-time period values were excluded as

difference between the groups. Neither age group nor gender was sig-

there were less than 21 days of CareLink™ CGM adherence data in a

nificantly associated with CGM adherence.

given 28 day period; for the remaining 32 time periods, “projected
CGM hours per 28 days” was calculated as described above.

There was an unexpected difference in CGM adherence among the
sites (Figure 1, Table 3) with a clear separation between the Simulta-

Univariate analysis showed that the Simultaneous Group had con-

neous and Delayed groups in three of the sites, favoring Simultaneous

sistently higher CGM adherence hours in all six time periods (Table 2).

Group, while in the other two sites CGM adherence rapidly decreased

The adjusted mean difference in CGM adherence hours between ran-

in both groups. The multivariate model identified the latter two sites as

domization groups was statistically significant at all time points, and

having significantly lower CGM adherence compared to the reference

showed increasing benefit of simultaneous CGM introduction over

site, with a difference of 87.4 (P = .016) and 126.9 (P < .001) fewer

time. The multivariate model showed that individuals in the Simulta-

hours per 28 days (3.1 and 4.5 hours per day respectively when each

neous Group used CGM 62.4 more hours per 28-day period (P = .007),

site's randomization groups were combined). There were no differences

equivalent to an extra 2.2 hours per day, when other factors were held

in baseline demographics of participants in the five sites.

constant. The proportion of participants in each randomization group
who wore CGM >60% of the time (equivalent to 403.2 hours per
28-day period) decreased for both groups over time, with proportion of
participants in the Simultaneous Group greater than in the Delayed

2.3 | Association between timing of CGM initiation
and HbA1c 6 months after CGM initiation

Group in all time periods. The difference was statistically significant in
periods 3, 4, and 5. The proportion of participants not using CGM

HbA1c was statistically different between randomization groups at

increased over time for both randomization groups with no significant

study entry (Table 1). For this reason, post hoc it was decided that the
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TABLE 1

Baseline Demographics of the Study Population

Patient Characteristics at Study Entry

Simultaneous Group (N = 70)

Delayed Group (N = 69)

P-value

Age in years (mean ± SD)

11.49 (3.34)

11.47 (3.35)

.963

Age 5 to 12 years

42/70 (60.0)

43/69 (62.3)

.779

Age 13 to 18 years

28/70 (40.0)

26/69 (37.7)

3.55 (3.14)

3.25 (2.95)

Age category in years (N, %)

Diabetes duration in years (mean ± SD)

.966

Child gender (N, %)

.676

Girls

30/70 (42.9)

32/69 (46.4)

Boys

40/70 (57.1)

37/69 (53.6)

Percentage

8.05 (1.01)

7.72 (0.88)

mmol/mol

64.5 (12.5)

60.9 (13.9)

62/70 (88.6)

59/69 (85.5)

HbA1c (mean ± SD) at study entry

.024

Ethnicity (N, %)

.192

Caucasian
African-American

3/70 (4.3)

0

Asian or Pacific Islander

2/70 (2.9)

4/69 (5.8)

Hispanic
Other

0

0

3/70 (4.3)

6/69 (8.7)

7 (10)

7 (10)

Number of episodes of severe hypoglycemia in the
12 months prior to study entry (N,%)

.485

T A B L E 2 Association between timing of CGM initiation relative to pump start and CGM adherence (expressed in hours per 28 days) over
next 6 months
Months
after
CGM
initiation
1

2

3

4

5

6

Randomization
Group

N
(Missing)

Unadjusted
Mean CGM
hours per
28 days (SD)

Adjusted mean
difference in CGM
adherence hours
between groupsa
62.4

Simultaneous

70 (0)

564.0 (91.0)

Delayed

67 (1)

505.1 (143.7)

Simultaneous

70 (0)

502.9 (166.8)

Delayed

67 (1)

455.8 (204.6)

Simultaneous

69 (1)

486.3 (177.9)

Delayed

67 (1)

408.0 (221.1)

Simultaneous

70 (0)

463.9 (199.4)

Delayed

66 (2)

386.7 (206.4)

Simultaneous

70 (0)

432.9 (212.1)

Delayed

65 (3)

355.4 (242.6)

Simultaneous

70 (0)

407.9 (224.1)

Delayed

65 (3)

340.2 (239.4)

SE

95%
Confidence
Interval (hours
per 28 days)

Pvalue

22.6

18.1 to 106.7

.006

Participants
using CGM
>60% of the
time (%)b

Pvalue

92.9

.061

80.6
67.5

23.6

21.1 to 113.8

.004

80.0

.455

73.1
72.5

26.3

20.8 to 124.2

.006

82.6

.016

62.7
77.5

30.3

18.1 to 137.0

.011

72.9

.017

51.5
82.5

35.1

13.7 to 151.4

.019

70.0

.035

50.8
87.6

40.4

8.3 to 166.9

.031

65.7

.113

50.8

a

60% CGM use is equivalent to 403.2 hours per 28 days.
Expressed in hours per 28 days; the adjusted mean hours was higher in the Simultaneous Group at all time points.

b

outcome measure HbA1c after 6 months of CGM use would be calcu-

Delayed Group (P = .01). A multivariate analysis exploring factors

lated two ways. Six months after CGM initiation, mean HbA1c in the

associated with HbA1c 6 months after CGM initiation identified base-

Simultaneous Group was 7.94% (SD 0.84%) and in the Delayed Group

line HbA1c (P < .001) and one of the study sites (P = .023) as the only

it was 7.94% (SD 0.91%) (P = .68). However the change in HbA1c

relevant parameters. In the multivariate model, randomization group

between study entry and 6 months after CGM initiation was −0.12%

was not significantly associated with HbA1c 6 months after CGM

(SD 0.91%) for Simultaneous Group and + 0.26% (SD 0.77%) for

initiation.
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T A B L E 3 Association between CGM adherence (expressed in hours per 28 days), randomization group, study site and parameters in mixed
effects model

Parameter

Coefficient

Randomization Group (Simultaneous)
Age Group

13-17

Gender (female)

95% Confidence Interval
(hours per 28 days)

SE

62.4

22.6

16.2

23.2

39.8

23.1

P-value

t

17.8 to 107.1

2.8

.007

−29.8 to 62.2

0.7

.487

−5.8 to 85.4

1.7

.086

Site 2

−69.7

33.4

−135.9 to −3.6

−2.1

.039

Site 3

−52.0

34.3

−119.9 to 15.9

−1.5

.132

Site 4

−87.4

35.7

−158.1 to −16.7

−2.5

.016

Site 5

−126.9

33.6

−193.3 to −60.4

−3.8

<.001

Time

−52.9

8.1

−68.7 to −37.1

−6.6

<.001

3.5

1.3

1.0 to 6.1

2.7

.007

Time2
Simultaneous group × time
Ethnicity (Caucasian)
Episode of severe hypoglycemia in the 12 months prior to
study entry

0.6

34.8

−68.2 to 69.5

0.0

.411

38.0

37.7

−36.6 to 112.5

1.0

.315

5.0

6.7

−8.1 to 18.1

0.8

.450

10.0

Female (95%CI)

9.5

Male (95%CI)

6−month A1c

9.0

8.5

8.0

7.5

7.0
0

100

200

300

400

500

600

Average CGM hours

F I G U R E 2 Association between CGM adherence hours per 28 days and HbA1C 6 months after CGM initiation as determined by ordinary
least squares regression

2.4

|

Exploratory analyses

Supporting Information Table 1), such that every additional 100 hours
of CGM use per 28-day period (3.57 hours per day) was associated

A significant negative association was found between average CGM

with a 0.38% (95% confidence interval 0.09-0.68%) reduction in

adherence hours and HbA1c 6 months after CGM initiation (Figure 2,

HbA1c (P = .013).

285

LAWSON ET AL.

A model investigating estimated area under the curve for propor-

and youth who were age 10 years and older complete the validated

tion of time spent with blood glucose <3.9 mmol/L (70 mg/dL) and

SOCRATES questionnaire14 at baseline and 6 months later, and while

average CGM adherence hours did not find a significant association

motivational stage was associated with glycemic control at trial entry,

between these two factors (P = .192), however study site was found

it did not predict future diabetes-related behavior or HbA1c. Our

to be associated with estimated time spent in hypoglycemia

CGM adherence results are supported by Moreno-Fernandez et al's

(P < .001). In contrast, increasing CGM use was significantly associ-

26 week study17 involving 22 adults with type 1 diabetes about to

ated with reduction in time spent with blood glucose >10 mmol/L

start pump therapy. Their participants were randomized to start CGM

(180 mg/dL) (P < .001). Study site was also associated with time spent

3 weeks before starting pump therapy or 3 weeks after. Those who

in hyperglycemia (P = .003) (Supporting Information Figure 2A,B).

started CGM before pump therapy had 84.6% CGM adherence compared with 64.0% in those who started pump therapy first. Hypoglycemia, measured by CGM and by number of hypoglycemia events,

2.5

Adverse events

|

was significantly lower in their early CGM group. Their study did not
include the LGS option. It is surprising that in our study, CGM that

There were four episodes of severe hypoglycemia in each randomiza-

offered LGS did not have an effect on frequency of hypoglycemia

tion group during the 12 months of the study. In the Simultaneous

measured as AUC < 4 mmol/L or on frequency of severe hypoglyce-

group, three of the four participants were using CGM with LGS active

mia, with four episodes over 6 months in each group. This was lower

at the time of the event. In the Delayed Group, two of the four partic-

than in the 12 months before the study, during which seven partici-

ipants were using CGM with LGS active at the time of the event.

pants in each group reported an episode of severe hypoglycemia. The

There were three episodes of DKA during the trial, and all occurred in

lack of effect on frequency or severity of hypoglycemia is likely

participants in the Delayed Group who were not using CGM at

because it was designed to be a pragmatic study with no minimum

the time.

A1c for participation and therefore many participants entered the
study with excellent control. As a result, there was a floor effect,
which would have impacted results in our study. CGM offering LGS

2.6

Patient satisfaction

|

was found to be associated with lower fear of hypoglycemia in participants and their parents as measured by the Hypoglycemia Fear

At the conclusion of the trial, participants were asked to rate on a

Scare.18

5-point Likert scale how likely they would be to continue CGM.

CGM adherence is known to be lower in children and youth com-

44.4% of children/youth, 64.0% of mothers, and 65.5% of fathers

pared to adults with type 1 diabetes.1,3,4,7 Mean CGM adherence in

reported they would be “likely” or “very likely” to continue CGM.

our study was similar to what has been reported previously in pediat-

There was no statistical difference in response distribution between

ric diabetes.1-3 There was a trend toward greater CGM adherence in

randomization groups.

female participants, which did not reach statistical significance
(P = .086). In our trial, at the 6-month mark, 65.7% of participants in
the Simultaneous group and 50.8% of those in the Delayed group

3

|

DISCUSSION

were using CGM over 60% of the time. This represented a significant
decrease in adherence compared to the first month of CGM use for

Our main conclusions were the following: first, that simultaneous initi-

both randomization groups, though the decrease was less in the

ation of CGM with the option of LGS and insulin pump therapy was

Simultaneous group. Previous studies have examined barriers to CGM

associated with greater CGM adherence in the first 6 months com-

adherence in adolescents, which include body image, loss of freedom,

pared to initiation of CGM with option of LGS 6 months after starting

pain, annoyance with alarms, and data overload.19,20 The addition of

pump therapy (though this effect varied between sites); second, that

CGM to the diabetes regimen may affect the child–parent relation-

there was no significant difference in mean HbA1c 6 months after

ship, especially if parents and children have different goals and expec-

CGM initiation although there was a significant difference in change

tations19 and may add to the already-significant burden of managing

in HbA1c favoring the Simultaneous Group; and third, that greater

diabetes on a day-to-day basis. It makes sense that introducing CGM

CGM adherence was associated with improved glycemic control at

and pump therapy together might decrease the perceived burden of

6 months.

CGM by combining it with the increased flexibility that pump therapy

Our first conclusion is consistent with our hypothesis that simul-

offers to youth.

taneous initiation of CGM and pump therapy would result in improved

One of the strengths of the CGM TIME Trial is the structured,

CGM adherence. This hypothesis was based on the idea that simulta-

stepwise, and specific CGM teaching approach, most of which we

neous initiation would capitalize on readiness for change that individ-

described in detail in a separate publication.13 Even with this degree

uals in the process of changing their insulin delivery method would be

of standardization, differences in personal approach and institutional

experiencing, while also reinforcing the concept that CGM is an inte-

culture introduce variability, and this may have contributed to the

gral part of pump therapy, as opposed to an optional addition. The

unexpected difference in intervention effect between study sites. The

readiness for change hypothesis was examined by having all parents

trial was conducted when sensor technology was relatively new.
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Three of the sites had considerable experience with the Medtronic

succeed, unlike many previous CGM trials.1,3,5 The between-site dif-

Pump CGM System prior to the study. In contrast, before the study,

ferences reflect the reality of managing a condition that depends on

the other two sites had rarely or never taught and supported children

the interaction of patients and the medical team.

and youth on the Medtronic Pump CGM System. An Australian

In conclusion, our data suggest that initiating CGM with the

study,21 piloted with two diabetes educators in Canada, examined dia-

option of LGS in a pediatric population with type 1 diabetes at the

betes educators' perceptions of factors that support and limit the use

time of pump initiation is preferable to afterwards. CGM devices that

of diabetes technologies such as CGM in people with T1D, and found,

have been approved since our study was completed are being started

while care was well intentioned, it was often not delivered with

successfully before pump therapy and with multiple daily injections.24

appropriate technology expertise. This demonstrates the importance

Our results, as well as those from previous studies, notably the STAR3

of comprehensive training and support for clinic staff on diabetes

trial,2 demonstrate that young patients (and their parents) are able to

technologies that are new to them so that they can teach and fully

adapt to both new technologies at once, and that the simultaneous

support patients and families on how to effectively use emerging

use of both devices has the potential to improve diabetes

technologies.

management.

Our second and third conclusions relate to effect of CGM on
HbA1c and the association between CGM adherence and glycemic
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